Boston Partners
HRMY icon

Boston Partners’s Harmony Biosciences HRMY Stock Holding History

Boston Partners’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.11M Sell
30,481
-12,462
-29% -$393K ﹤0.01% 665
2026
Q1 		$1.2M Sell
42,943
-666,000
-94% -$21.8M ﹤0.01% 626
2025
Q4 		$26.4M Sell
708,943
-45,009
-6% -$1.48M 0.03% 342
2025
Q3 		$20.7M Buy
753,952
+148,457
+25% +$5.11M 0.02% 368
2025
Q2 		$19.4M Buy
+605,495
New +$19.5M 0.02% 360

Other funds holding HRMY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Boston Partners's HRMY Position: Q2 2026 in Review

Boston Partners reduced its Harmony Biosciences (HRMY) stake by 29% in Q2 2026, selling an estimated $393K and leaving 30,481 shares worth $1.11M. The position accounts for ﹤0.01% of the portfolio, ranked #665.

Boston Partners first reported a position in HRMY in Q2 2025 and has held it in 5 quarters since. The position peaked at $26.4M in Q4 2025. 327 funds tracked by Wall St. Rank hold HRMY as of Q2 2026.

  • Boston Partners held 30,481 shares of Harmony Biosciences worth $1.11M as of Q2 2026.
  • Boston Partners sold 12,462 Harmony Biosciences shares in Q2 2026, an estimated $393K.
  • Harmony Biosciences made up ﹤0.01% of Boston Partners's portfolio in Q2 2026, its #665 holding.
  • Boston Partners first reported a position in Harmony Biosciences in Q2 2025 and has held it in 5 quarters since.
  • Boston Partners's Harmony Biosciences position peaked at $26.4M in Q4 2025.
  • 327 funds tracked by Wall St. Rank held Harmony Biosciences as of Q2 2026.

Based on Boston Partners's 13F filing for Q2 2026, filed 4 Aug 2026.